Ibrexafungerp

Major

Ibrexafungerp Ribociclib Kisqali Increased ibrexafungerp exposure Details Ibrexafungerp Rifabutin Mycobutin Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Rifampin Rifadin Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ibrexafungerp Ritonavir Norvir Increased ibrexafungerp exposure Details Ibrexafungerp Roflumilast Daliresp Increased roflumilast exposure and an increased risk of roflumilast-related adverse events Details Ibrexafungerp Saquinavir Increased ibrexafungerp exposure Details Ibrexafungerp St John's Wort Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Suzetrigine Journavx Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Ibrexafungerp Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Ibrexafungerp Telaprevir Increased ibrexafungerp exposure Details Ibrexafungerp Telithromycin Increased ibrexafungerp exposure Details Ibrexafungerp Tramadol ConZip Increased traMADol exposure and an increased risk of seizures, serotonin syndrome and opioid toxicity Details Ibrexafungerp Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Ibrexafungerp Venetoclax Venclexta Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Ibrexafungerp Voriconazole Vfend Increased ibrexafungerp exposure, an increased ibrexafungerp-related adverse reactions, an increased voriconazole exposure and an... Details Ibrexafungerp Ketoconazole Topical Extina® Foam Increased ibrexafungerp exposure Details Ibrexafungerp Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Ibrexafungerp Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Ibrexafungerp Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Ibrexafungerp Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Ibrexafungerp Nafcillin Injection Unipen® Injection Decreased ibrexafungerp plasma concentrations Details

Moderate

Ibrexafungerp Dofetilide Tikosyn Increased dofetilide exposure Details Ibrexafungerp Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Ibrexafungerp Hydrocortisone Injection A-Hydrocort® Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Ibrexafungerp Kratom Increased CYP3A substrate exposure Details Ibrexafungerp Lumefantrine Increased artemether/lumefantrine exposure and an increased risk of potentiated QT prolongation Details Ibrexafungerp Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Ibrexafungerp Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ibrexafungerp Seladelpar Increased seladelpar exposure Details Ibrexafungerp Tenofovir Alafenamide Increased tenofovir alafenamide exposure and an increased risk of tenofovir alafenamide-related adverse effects Details